Acute Chest Syndrome

This research aims to learn more about vitamin C deficiency in patients with either acute or chronic diseases. It focuses on understanding how symptoms change over time and how well patients tolerate treatment. The study involves patients diagnosed with vitamin C deficiency either by lab tests or based on symptoms such as fatigue, infections, bleeding gums, joint pain, and poor wound healing. The study observes patients treated with Vitamin C Injektopas® 7.5 g, given for an expected average of about 3 weeks for acute diseases or 12 weeks for chronic diseases. Two groups are included: those with acute underlying diseases and those with chronic underlying diseases, both receiving this vitamin C therapy during the study period. Participants will be followed to assess changes in general and disease-specific symptoms, as well as treatment tolerability and overall effectiveness from the patient's perspective. Researchers will also record the number of vitamin C infusions and measure quality of life for chronic disease patients. The study duration ranges up to approximately 12 weeks, with evaluations at the last visit to understand symptom improvement and treatment impact.

Researchers are evaluating the accuracy and safety of the new Syai Tag system for continuous glucose monitoring in patients admitted to intensive internal care. With nearly 150,000 people in Slovenia living with diabetes, monitoring blood sugar levels closely is essential to prevent complications. This study involves patients in the intensive care unit who require blood sugar monitoring during their stay. Participants will have two small sensors placed on each upper arm to continuously measure blood sugar levels using the Syai Tag system, though these readings will not be visible to medical staff. At the same time, healthcare professionals will carry out routine blood sugar measurements. The study compares the accuracy of the continuous glucose monitoring system to standard blood sugar tests over the duration of the ICU stay, up to 14 days. During the study, researchers will monitor sensor uptime and compare glucose readings from the Syai Tag system to arterial blood gas measurements. They will also evaluate the impact of noradrenaline on measurement accuracy and the lifespan of the sensors in ICU conditions. The procedure is safe and painless, and patients will continue to receive the usual high-quality care throughout their participation.

Researchers are conducting a study called Acutelines, a large data and biobank project at the University Medical Center Groningen in the Netherlands. It focuses on patients with a wide range of acute medical conditions who present to the Emergency Department. The goal is to improve how acute diseases are recognized and treated, understand their outcomes, and support personalized medicine by collecting detailed clinical data, imaging, and biomaterials over time. Participants have their medical information, including demographics, health status, medical history, vital signs, diagnostic tests, and treatments, systematically collected. Biomaterials such as blood, urine, feces, and hair are gathered from patients who meet certain severity criteria. Data collection occurs during hospital admission, including continuous monitoring, and continues with follow-ups at 3 months, 1 year, 2 years, and 5 years after the initial emergency visit. Throughout the study, various assessments are performed, such as quality of life, physical functioning, mental health, symptoms, and hospital length of stay. Researchers collect data on mortality and other health outcomes for up to 50 years. The study uses digital tools to automate data capture and integrates information from multiple healthcare sources. Participants will be monitored closely during hospitalization and at scheduled intervals afterward to help improve understanding and treatment of acute diseases.

Researchers are studying the safety and effectiveness of intra-arterial Tenecteplase (TNK) as an additional treatment in adults with acute ischemic stroke caused by large vessel blockages in the anterior circulation of the brain (Internal Carotid Artery and Middle Cerebral Arteries M1 and M2 segments). This Phase 2 and 3 trial focuses on patients who have undergone mechanical thrombectomy using FDA-approved devices and achieved successful reperfusion (mTICI 2b or higher). The goal is to see if adding TNK improves recovery outcomes after stroke. Participants will be randomly assigned to receive either intra-arterial TNK following their mechanical thrombectomy or the best medical care without TNK. The study compares these two approaches to evaluate treatment benefits and risks. This trial will enroll adults aged 18 to 85 years who meet specific clinical and imaging criteria related to their stroke and thrombectomy results. During the study, patients will be monitored closely with assessments including the Modified Rankin Scale (mRS) at 90 days to measure disability, along with safety checks such as monitoring for brain hemorrhage and neurological worsening within 24 hours after treatment. Additional outcomes like functional independence, mortality rates, revascularization grades, and infarct volume will also be tracked. The total follow-up period includes visits up to 90 days after treatment to evaluate both efficacy and safety.

Researchers are investigating how droplet digital PCR (ddPCR) can help identify harmful bacteria early in patients admitted to the intensive care unit (ICU) with sepsis. This observational study aims to track the presence and amount of bacteria in the blood over time and understand how these bacteria relate to patients' clinical conditions and outcomes. The study is conducted at a single center and focuses on critically ill ICU patients with their first sepsis diagnosis. Patients in this study will have their blood tested at various points from admission up to 28 to 30 days or until they leave the ICU. The ddPCR method will be used to monitor the amount of bacterial genetic material in their blood dynamically. This ongoing monitoring helps researchers observe changes in bacterial presence during the critical period of sepsis treatment. Participants will undergo repeated blood sampling at specified intervals: days 0, 2-3, 4-5, 6-7, 8-9, 10-12, 13-15, 20-22, and 28-30 after ICU admission. Researchers will measure bacterial nucleic acid loads at these times and track survival status at 28 days after the initial sepsis diagnosis. This monitoring helps assess the relationship between bacterial levels and patient outcomes throughout the observation period.

This research aims to observe the relationship between different therapy strategies and treatment outcomes for patients in intensive care units (ICUs) under real-world conditions. It focuses on three initial risk groups—high, intermediate, and low—based on factors such as frailty, disease severity, and the number of organ systems requiring support. The study evaluates three key endpoints: burden of care, mortality, and supply costs. The study includes ICU patients who either stay for at least 72 hours or die within 72 hours of admission. Participants are categorized into risk groups according to the Clinical Frailty Scale, the Simplified Acute Physiology Score II, and the number of organ systems needing support or replacement. The study observes therapy strategies such as maximal therapy, withholding treatment, or withdrawing treatment, assessing their association with treatment success across these groups. Participants will be monitored over an 18-month period to measure burden of care, mortality rates, and supply costs. Data collection will occur under typical clinical conditions without altering standard care. The study systematically tracks patient outcomes related to therapy strategies, aiming to provide insights into intensive care practices and associated resource use.

Researchers are evaluating whether combining dynamic CT myocardial stress perfusion, CT fractional flow reserve (FFR-CT), and coronary CT angiography can improve health outcomes and symptom relief in patients with stable chest pain syndromes suspected or confirmed to have ischemic heart disease. This randomized, open-label trial compares this combined imaging guided treatment strategy against conventional management in patients with chronic chest pain. The study is conducted in the Capital Region of Copenhagen, Denmark, focusing on reducing major adverse cardiovascular events and improving clinical care. Participants are assigned to one of two groups: one receives treatment guided by the combined dynamic CT stress myocardial perfusion, FFR-CT, and CT coronary angiography results; the other follows standard clinical evaluation and treatment practices. The imaging-based strategy involves a team including a cardiac CT specialist, invasive cardiologist, thoracic surgeon, and cardiology nurse specialist who determine treatment plans such as referral for percutaneous coronary intervention, coronary artery bypass surgery, or optimal medical therapy. Both groups undergo evaluation and treatment as per their assigned strategy. During the study, participants will be monitored over several years with key assessments including major adverse cardiovascular events over 3 years, symptom relief measures like the Seattle Angina Questionnaire at 3 and 12 months, quality of life assessments, hospitalization events, and mortality tracked up to 10 years. Additional data on diagnostic test usage, radiation exposure, procedural complications, and diagnoses explaining symptoms will also be collected. This comprehensive follow-up aims to understand the impact of the imaging-guided strategy on clinical outcomes and patient well-being.

This research aims to develop and improve a decision support system for patients experiencing chest pain before they reach the hospital. It focuses on evaluating how well a machine learning model can assist emergency medical services in assessing these patients. The study addresses the challenge of safely directing patients to the right level of care, balancing timely treatment for serious conditions like heart attacks or strokes with avoiding unnecessary hospital visits that may cause delays or overcrowding. Participants will be asked questions at the scene about their medical history and pain details, and a blood sample for troponin and glucose will be taken and analyzed immediately. The study collects routine medical record data and scene measurements to validate and further develop the decision support model. Participants will continue to receive standard care according to guidelines, typically transport to an emergency department if needed. Throughout the study, researchers will monitor clinical outcomes including time-sensitive conditions, deaths within seven days, and adverse events within 72 hours after ambulance service inclusion. Data from the initial assessment, blood tests, and medical records will help evaluate the model's predictive performance. The study is observational, and participant involvement includes answering questions and consenting to data and sample collection. The total duration extends from emergency contact through hospital discharge and follow-up periods up to 100 days.

Researchers are investigating whether matching the sex of blood donors and recipients for red blood cell (RBC) transfusions can improve patient outcomes in critically ill adults admitted to intensive care units (ICUs). This randomized controlled trial will compare mortality rates between patients receiving sex-matched RBC transfusions and those receiving sex-mismatched RBC transfusions. Previous studies and biological evidence suggest that sex-matched transplants may benefit patients, but current transfusion practices do not consider donor-recipient sex. The study will enroll adult ICU patients requiring RBC transfusions and randomly assign them to receive either sex-matched or sex-mismatched blood. The trial will take place across multiple Canadian sites and include two groups: one receiving sex-matched RBC transfusions and the other sex-mismatched transfusions. The primary outcome is 30-day mortality, with secondary outcomes including in-hospital mortality, 90-day mortality, time to death, changes in hemoglobin and kidney function, ICU and hospital stay length, transfusion reactions, and cost-effectiveness. Participants will be monitored from the time of randomization through 30 to 90 days post-transfusion, with assessments including blood tests to measure hemoglobin and creatinine levels, tracking of transfusion products used, and recording of adverse reactions. Researchers will collect data on patient outcomes, transfusion details, and healthcare resource use. The study aims to provide evidence on whether sex-matched transfusions improve survival and inform future blood transfusion practices and blood inventory management.

This trial focuses on adults aged 18 and older admitted to Acute Admission Units (AAU) with non-urgent health complaints such as coughing, back pain, or abdominal discomfort. It aims to evaluate whether using the medidux132 smartphone app after discharge can reduce the rates of readmissions, emergency hospitalizations, and consultations with other medical providers within 7 days. The study compares this app-based monitoring approach with standard post-discharge care to understand its impact on patient outcomes. Participants are randomly assigned to either the intervention arm, where they use the medidux132 app to record symptoms and vital signs daily for 7 days after discharge, or the control arm, which receives usual care without the app. The app provides prompts and guidance to help users manage their symptoms and decide if further medical attention is needed. Follow-up assessments occur at 7 and 28 days post-discharge for all participants to evaluate symptom changes and healthcare use. During the study, participants will complete symptom tracking and vital sign monitoring through the app if in the intervention group, and both groups will attend follow-up consultations at day 7 and day 28. Researchers will measure outcomes including readmission rates, emergency hospitalizations, consultations with medical providers, symptom severity, and app usability. The primary outcome is the incidence of these events within 7 days after initial admission, with additional monitoring up to 28 days to assess longer-term effects.